Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

932
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
932
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

664
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
664
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

613
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
613
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

624
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
624
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

740
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
740

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteopathic Manipulative Treatment as a Complementary and Integrative Approach for Cancer Supportive Care: A Systematic Review.

Cancers·2026
Same author

Potential of Dietary Agent Daidzein in Cancer Prevention and Treatment: Opportunities and Challenges.

Cancers·2026
Same author

Kavain for health promotion and disease mitigation: Pharmacological promise and therapeutic perspectives.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Targeting signaling cascades by bioactive phytocompounds in osteosarcoma: A novel therapeutic approach.

Pharmacology & therapeutics·2026
Same author

Mechanistic insights into the anticancer potential of ruthenium(II) paracymene complexes of phenolic acids.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Targeting Pathways Implicated in Cholesterol Metabolism for Novel Cancer Therapy.

Cancers·2026

Related Experiment Video

Updated: Mar 29, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K

Can Probiotics Cure Inflammatory Bowel Diseases?

Siva Kumar Korada, Nagendra Sastry Yarla, Anupam Bishayee

  • 1National Institute of Food Technology Entrepreneurship and Management (NIFTEM), Sonepat, Haryana, India. vijendramishra.niftem@gmail.com.

Current Pharmaceutical Design
|December 10, 2015
PubMed
Summary

Probiotics, live beneficial microorganisms, show promise in managing inflammatory bowel diseases (IBD) by improving gut health. Further research is needed to standardize probiotic use for IBD prevention and treatment in humans.

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.4K

Related Experiment Videos

Last Updated: Mar 29, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

13.0K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:34

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

1.4K

Area of Science:

  • Gastroenterology
  • Microbiology
  • Immunology

Background:

  • Gastrointestinal disorders, including inflammatory bowel diseases (IBD), are often linked to microbial dysbiosis and impaired gut barrier function.
  • The exact causes of IBD remain unclear, but specific pathogens and multifactorial elements contribute to its development.
  • Probiotic research is emerging as a significant area due to positive experimental outcomes in IBD.

Purpose of the Study:

  • To review the role of gut microflora in host health and its impact on IBD.
  • To explore the mechanisms of probiotic action and their potential in IBD prevention.
  • To discuss existing therapies for IBD and the need for standardized probiotic research.

Main Methods:

  • Literature review of studies on gut microbiota, IBD, and probiotics.
  • Analysis of existing therapeutic approaches for IBD.
  • Examination of evidence supporting probiotic efficacy in IBD models.

Main Results:

  • Microbial dysbiosis is a key factor in IBD pathogenesis.
  • Probiotics, defined as live microorganisms conferring health benefits, may improve gut colonization and offer a prophylactic effect.
  • Evidence suggests a beneficial role for probiotics in IBD prevention and management.

Conclusions:

  • Probiotics hold potential as a therapeutic strategy for IBD.
  • Standardization of probiotic methodologies and human trials are crucial for clinical application.
  • Understanding the gut microbiome's role is essential for advancing IBD treatment.